Logo of npgopen
PMC full text:
Published online 2023 Oct 30. doi: 10.1038/s41591-023-02660-6
Copyright/LicenseRequest permission to reuse

Extended Data Fig. 10

An external file that holds a picture, illustration, etc. Object name is 41591_2023_2660_Fig15_ESM.jpg
Relationship between radiology and pathology and other clinical/biomarker correlates.

a, Patients with LN involvement by imaging at baseline and by pathology at resection by treatment arm. b, Radiographic (BOR per RECIST1.1) and pathologic response (%RVT) in PT. c, Radiographic (BOR per RECIST1.1) and pathologic response (%RVT) in LN, across treatment arms. d, Radiographic (BOR per RECIST1.1) and pathologic response (%RVT) in LN by treatment arm. e, ctDNA clearance and pathologic response (%RVT) in PT. f, ctDNA clearance and pathologic response (%RVT) in LN, across treatment arms. g, ctDNA clearance and pathologic response (%RVT) in LN by treatment arm. BOR denotes best overall response; CR complete response; LN, lymph node; MPR, major pathologic response; NE, not evaluable; pCR, pathologic complete response; PD, progressive disease; PR, partial response; PT, primary tumor; RECIST1.1, Response Evaluation Criteria in Solid Tumors version 1.1; RVT, residual viable tumor; SD, stable disease. aData were not reported for 1 patient. bctDNA data were not available/not evaluable for 108 patients. cctDNA data were not available/not evaluable for 93 patients. dctDNA data were not available/not evaluable for 109 patients. ectDNA data were not available/not evaluable for 53 patients. fctDNA data were not available/not evaluable for 56 patients.

Images in this article

  • Fig. 1
  • Fig. 2
  • Fig. 3
  • Fig. 4
  • Fig. 5
  • Extended Data Fig. 1
  • Extended Data Fig. 2
  • Extended Data Fig. 3
  • Extended Data Fig. 4
  • Extended Data Fig. 5
  • Extended Data Fig. 6
  • Extended Data Fig. 7
  • Extended Data Fig. 8
  • Extended Data Fig. 9
  • Extended Data Fig. 10

Click on the image to see a larger version.